Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.

ABSTRACT:

Background

Cancer cachexia exhibits decreased albumin and associates with short overall survival (OS) in patients with non-small cell lung cancer (NSCLC), but whether on-treatment albumin changes associate with OS in NSCLC patients treated with immune checkpoint inhibitors (ICIs) and combination chemoimmunotherapy has not been thoroughly evaluated.

Patients and methods

We conducted a single-center retrospective study of patients with advanced NSCLC who received first-line ICI with or without chemotherapy between 2013 and 2020. The association of pretreatment albumin and early albumin changes with OS was evaluated using Kaplan-Meier method and Cox regression models.

Results

A total of 210 patients were included: 109 in ICI cohort and 101 in ICI + Chemo cohort. Within a

SUBMITTER: Guo Y 

PROVIDER: S-EPMC9149057 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature